The stocks that investors shied away from the most this week could be poised to rebound if the market makes a comeback. Stocks have taken a severe beating, with many investors selling positions after President Donald Trump unveiled his latest tariff policies late Wednesday. All three major averages closed in the red this week, with the tech-heavy Nasdaq Composite leading the losses, falling 10%. Investors are trying to play it safe, still cautious that the sell-off could get worse. Citi Wealth chief investment officer Kate Moore told CNBC's " Squawk Box " Thursday morning that " the uncertainty factor is just starting ," and she that she didn't "want to be adding to risk right now." Still, if the market does go through a relief rally, there a certain stocks that are due for a bounce, according to widely used technical analysis metrics. This type of analysis is used for quick trading and not for finding long-term investing ideas. CNBC Pro used its stock screener tool to identify the most oversold and overbought stocks on Wall Street by weighing their 14-day relative strength index, or RSI. An RSI reading below 30 suggests a stock is oversold and could bounce back in the event of a market rebound. Conversely, a 14-day RSI above 70 indicates that a stock may be overbought and could soon be due to weaken. Oversold stocks One prominent name on the oversold list was GE Healthcare , which has an RSI of just 10.4. The average price target for the medical technology firm implies that shares could rise 59% from their current level. Last month, Goldman Sachs analyst David Roman upgraded the stock to a buy from neutral. Simultaneously, he hiked his price target to $100 from $85, indicating potential 65% upside from the stock's Friday close. As a catalyst, Roman pointed to the company's stabilizing sales in China, at the same time as he also believes GE Healthcare can adequately hedge against Trump's new tariffs. "We … believe that a faster turnaround in China and [profit-and-loss] leverage can more than offset the known tariff risk," he said. "As is the case across global MedTech, it is hard to quantify the risk of future potential tariffs, but we do not see GE Healthcare as disproportionately exposed vs. any other company to Mexico, Canada, or the EU." With an RSI of 13, Seagate Technology was also one of Wall Street's most oversold stocks. The average analyst price target implies a potential 79% rally. In March, Morgan Stanley singled out the stock as one of its top picks. "STX benefits from accelerating data growth, which drives storage demand in the cloud and [on-premises]," wrote analyst Erik Woodring. "We believe that we are still in the middle of the cycle upturn." Woodring's $138 price target is approximately 107% above the stock's Friday close. Overbought stocks On the other hand, the market sell-off drove investors into many consumer staples and income plays thought to be immune from a trade war. These names could be due for underperformance, according to the technical metrics, if the market does right itself again. This week's most overbought stocks included Monster Beverage , which manufactures its namesake energy drink. The stock currently has an RSI of 76, and the average price target implies 5% downside. On Tuesday, Goldman Sachs highlighted Monster Beverage as a preferred idea "given strong dollar driven top and bottom line growth that will outpace peers." The Wall Street bank said that these solid fundamentals should support Monster Beverage against a background of slower job growth and higher inflation due to tariffs, which could weigh on household incomes. "Given our slightly more cautious outlook for the consumer relative to where we were in January 2025, we do highlight somewhat more defensive names or those with idiosyncratic drivers that can offset any potential negative consumer impact," the investment bank wrote. With an RSI of 77, real estate investment trust American Tower also made the overbought screen. The average price target for the stock corresponds to upside of just 1%. Morgan Stanley assumed research coverage of American Tower with an overweight rating earlier this week, with analyst Benjamin Swinburne setting a price target of $250, implying upside of 14% over the coming 12 months. "We see AMT as offering an attractive risk/reward in the context of the U.S. Tower REITs," Swinburne wrote. "We see accelerating growth through 2025 and into 2026, driven by the roll off of Sprint-related churn, contribution from its Data Center business, fading FX headwinds and on the assumption the company executes on cost initiatives ahead." Get Your Ticket to Pro LIVE Join us at the New York Stock Exchange! Uncertain markets? Gain an edge with CNBC Pro LIVE , an exclusive, inaugural event at the historic New York Stock Exchange. In today's dynamic financial landscape, access to expert insights is paramount. As a CNBC Pro subscriber, we invite you to join us for our first exclusive, in-person CNBC Pro LIVE event at the iconic NYSE on Thursday, June 12. Join interactive Pro clinics led by our Pros Carter Worth, Dan Niles, and Dan Ives, with a special edition of Pro Talks with Tom Lee. You'll also get the opportunity to network with CNBC experts, talent and other Pro subscribers during an exciting cocktail hour on the legendary trading floor. Tickets are limited!
